PMID- 20450543
OWN - NLM
STAT- MEDLINE
DCOM- 20121105
LR  - 20151119
IS  - 1000-503X (Print)
IS  - 1000-503X (Linking)
VI  - 32
IP  - 2
DP  - 2010 Apr
TI  - [Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung 
      cancer].
PG  - 151-6
LID - 10.3881/j.issn.1000-503X.2010.02.005 [doi]
AB  - OBJECTIVE: To explore the efficacy and safety of erlotinib monotherapy for 
      advanced non-small cell lung cancer (NSCLC). METHODS: Totally 50 patients with 
      advanced NSCLC received oral erlotinib 150 mg/d treatment, and tumor specimen in 
      19 patients were collected for epidermal growth factor receptor (EGFR) gene 
      mutation tests. Median survival (MS) was calculated using the Kaplan-Meier 
      method. RESULTS: The most common adverse events (AEs) were skin rash (96%) and 
      diarrhea (32%). The overall survival (OS) of all patients was 21.8 months 95% 
      confidential interval (CI): 17.1-26.4 months and the median progression-free 
      survival (PFS) of all patients was 7.0 months (95% CI: 3.9-10.1 months). EGFR 
      mutation analysis showed gene mutation in 8 cases and wild type in 11 cases. The 
      objective response rate in patients with or without EGFR gene mutations were 
      62.5% and 9.1%, respectively (chi(2)=6.631, P=0.036). PFS in patients with or 
      without EGFR gene mutations were 16.330 (95% CI: 2.803-29.857 months) and 5.570 
      months (95% CI: 2.441-8.699 months), respectively (chi(2)=8.799, P=0.003). 
      CONCLUSION: Erlotinib monotherapy is safe and effective for some Chinese NSCLC 
      patients after failure of prior chemotherapy.
FAU - Wang, Meng-zhao
AU  - Wang MZ
AD  - Department of Respiratory Medicine, PUMC Hospital, CAMS and PUMC, Beijing 100730, 
      China. mengzhaowang@sina.com
FAU - Zhang, Xiao-tong
AU  - Zhang XT
FAU - Zhang, Xin-yong
AU  - Zhang XY
FAU - Zhang, Li
AU  - Zhang L
FAU - Zhong, Wei
AU  - Zhong W
FAU - Xu, Li-yan
AU  - Xu LY
FAU - Li, Long-yun
AU  - Li LY
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao
JT  - Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
JID - 8006230
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Quinazolines)
RN  - DA87705X9K (Erlotinib Hydrochloride)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Chi-Square Distribution
MH  - Erlotinib Hydrochloride
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Quinazolines/adverse effects/*therapeutic use
MH  - Regression Analysis
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2010/05/11 06:00
MHDA- 2012/11/06 06:00
CRDT- 2010/05/11 06:00
PHST- 2010/05/11 06:00 [entrez]
PHST- 2010/05/11 06:00 [pubmed]
PHST- 2012/11/06 06:00 [medline]
AID - 10.3881/j.issn.1000-503X.2010.02.005 [doi]
PST - ppublish
SO  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010 Apr;32(2):151-6. doi: 
      10.3881/j.issn.1000-503X.2010.02.005.